FDA Review of Previously-Rejected Arthritis Drug comes with conditions FDA is reconsidering approval for previously rejected arthritis drug by Eli Lilly and Incyte. However,
10 Jul, 2018
06 Feb, 2018
Top 5 healthcare industry predictions for the year 2018 In 2017, the healthcare industry saw several trends in healthcare technology advancement from FDA’s move to ease the
13 Nov, 2017
The e-cigarettes are now being brought under the purview of guideline and regulations by the Tobacco Products Directive 2014/14/EU (TPD), under the new rules for
13 Nov, 2017
On 22 November 2017, the European Medicines Agency (EMA) will launch a new and improved version of EudraVigilance, the European information system of suspected adverse
13 Nov, 2017
A welcome move by EMA on its first public hearing where Patients, carers, doctors, pharmacists and academia shared their experience and reviews on the usage of a medicine that
13 Nov, 2017
The European Medicines Agency (EMA) and the European Commission have updated the annex to the European Commission guideline on excipients in the labelling and package leaflet
EMA’s PRAC conducted a referral procedure to examine whether there is any evidence of a causal link between HPV vaccination and two syndromes, complex regional pain syndrome
13 Nov, 2017
Brexit has led to European Medicines Agency(EMA) to prepare a plan to enable business continuity of the Agency’s operation. The Brexit Preparedness plan prioritised on the
13 Nov, 2017
Stelara: Johnson and Johnson’s received FDA approval for Stelara to treat adolescents aged 12 and older with moderate to severe plaque psoriasis. The data received by the FDA
13 Nov, 2017
Five signals were detected from EU Spontaneous Reporting Systems • Apixaban – ELIQUIS; dabigatran – PRADAXA; edoxaban – LIXIANA; rivaroxaban – XARELTO
